II. Keynote
IV. Preclinical Section
1. Preclinical Strategy for Evaluation of Novel Mechanism Compounds
2. Unique Challenges in Study Designs
3. Evaluation of Biologics
V. Clinical Section
1. Approaches to identify and classify AEs and aberrant behaviors related to abuse, misuse and diversion during clinical drug development
2. Statistical Considerations for Human Abuse Potential Studies
3. Assessments of Physical Dependence in Clinical Setting
VI. Post-Marketing Section